AQP9 and metabolic dysfunction-associated steatotic liver disease: In another report, AQP9 expression was shown to be reduced in patients with non-alcoholic liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), translating its downregulation into a compensatory mechanism against TG accumulation in fatty liver [92].